| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0360-3016(01)01671-6 |
| P698 | PubMed publication ID | 11567823 |
| P2093 | author name string | Z Fan | |
| L Milas | |||
| K K Ang | |||
| S Nasu | |||
| P2860 | cites work | The epidermal growth factor receptor and its inhibition in cancer therapy | Q33716127 |
| Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies | Q72856071 | ||
| The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma | Q73091527 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 474-477 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. | |
| P478 | volume | 51 |
| Q37975010 | A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer |
| Q40628684 | Anti‐erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours |
| Q39939644 | Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer |
| Q42423159 | Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial |
| Q36668224 | Cetuximab in the treatment of head and neck cancer |
| Q39509472 | Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy |
| Q37262663 | Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A |
| Q37806149 | Chemoradiotherapy for cervical cancer in 2010 |
| Q35037705 | Chemoradiotherapy: emerging treatment improvement strategies |
| Q36212891 | Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. |
| Q36795322 | Combination of radiotherapy with EGFR antagonists for head and neck carcinoma |
| Q51344874 | Comparison between weekly cisplatin-enhanced radiotherapy and cetuximab-enhanced radiotherapy in locally advanced head and neck cancer: first retrospective study in Asian population. |
| Q39635478 | Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models |
| Q44506186 | Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody |
| Q44306493 | EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor |
| Q35552515 | Epidermal growth factor receptor and its inhibition in radiotherapy:in vivofindings |
| Q28282037 | Exploring the role of cancer stem cells in radioresistance |
| Q35538759 | Feasibility of cetuximab and chemoradiotherapy combination in Chinese patients with unresectable stage III non-small cell lung cancer: a preliminary report |
| Q36982644 | Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers |
| Q37628728 | Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors |
| Q37470072 | Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation |
| Q79670956 | IFHNOS Global Continuing Education Program. Current concepts in head & neck surgery and oncology 2008 |
| Q36487722 | Increased expression of pAKT is associated with radiation resistance in cervical cancer |
| Q36175239 | Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer |
| Q38757690 | Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. |
| Q36303867 | Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors |
| Q38869420 | Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology |
| Q35024744 | Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer |
| Q34124274 | Molecular radiobiology: the state of the art |
| Q37458175 | Molecular therapy in head and neck oncology |
| Q34996001 | Novel techniques in the delivery of radiation in pediatric oncology |
| Q37676970 | Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function |
| Q44608845 | Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse |
| Q38973520 | Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase |
| Q34194320 | The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer |
| Q34610495 | The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications |
| Q52011134 | The epidermal growth factor receptor mediates radioresistance. |
| Q36210876 | The role of cetuximab in the treatment of squamous cell cancer of the head and neck |
| Q37766529 | The role of targeted agents in preoperative chemoradiation for rectal cancer |
| Q37015715 | The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers |
| Q54490610 | [Experimental tumor therapy]. |
| Q54493763 | [Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma]. |
Search more.